Trending

psoriasis

J&J trumpets new data from Tremfya as psoriasis market braces for biosimilars

J&J trumpets new data from Tremfya as psoriasis market braces for biosimilars

Humira biosimilars set to launch in EU next month

X

J&J trumpets new data from Tremfya as psoriasis market braces for biosimilars

https://pharmaphorum.com/news/jj-trumpets-new-data-from-tremfya-as-psoriasis-market-braces-for-biosimilars/

J&J’s Tremfya gets funding in Germany and UK

J&J’s Tremfya gets funding in Germany and UK

Johnson & Johnson’s psoriasis drug Tremfya has been given the green light for funding by cost-effectiveness bodies in

X

J&J’s Tremfya gets funding in Germany and UK

https://pharmaphorum.com/news/jjs-tremfya-funding-germany-uk/

FDA approves UCB’s Cimzia in plaque psoriasis

FDA approves UCB’s Cimzia in plaque psoriasis

The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis

X

FDA approves UCB’s Cimzia in plaque psoriasis

https://pharmaphorum.com/news/fda-ucbs-cimzia-plaque-psoriasis/

Escalier raises $19m to fund novel psoriasis pill

Escalier raises $19m to fund novel psoriasis pill

Escalier Biosciences, a privately-held biopharma company based in The Netherlands, has raised $19 million to help advance its

X

Escalier raises $19m to fund novel psoriasis pill

https://pharmaphorum.com/news/escalier-raises-19m-fund-novel-psoriasis-pill/

Novartis trumpets long-term data for Cosentyx in psoriasis

Novartis trumpets long-term data for Cosentyx in psoriasis

Novartis is hoping that new real world data will help its psoriasis drug Cosentyx stay ahead of rivals.

X

Novartis trumpets long-term data for Cosentyx in psoriasis

https://pharmaphorum.com/news/novartis-trumpets-long-term-data-cosentyx-psoriasis/

AbbVie to file long-acting psoriasis contender

AbbVie to file long-acting psoriasis contender

AbbVie hopes risankizumab will rebuild sales after Humira patent expires

X

AbbVie to file long-acting psoriasis contender

https://pharmaphorum.com/news/abbvie-eyes-global-filings-next-gen-psoriasis-drug/

Bioelectronic wearable shows promise in psoriasis

Bioelectronic wearable shows promise in psoriasis

Thync’s bioelectronic wearable significantly reduced symptoms in psoriasis patients within four weeks of use.

X

Bioelectronic wearable shows promise in psoriasis

https://pharmaphorum.com/news/bioelectronic-wearable-shows-promise-psoriasis/

J&J’s psoriasis drug faces crowded market after US approval

J&J’s psoriasis drug faces crowded market after US approval

J&J taking on next gen drugs from Novartis, Eli Lilly, and Valeant.

X

J&J’s psoriasis drug faces crowded market after US approval

https://pharmaphorum.com/news/jj-psoriasis-us-approval/

Novartis’ psoriasis drug gets label boost

Novartis’ psoriasis drug gets label boost

New label shows Cosentyx is superior to J&J’s rival in long-term.

X

Novartis’ psoriasis drug gets label boost

https://pharmaphorum.com/news/novartis-cosentyx-gets-label-boost/

1 2 3

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com